echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > All Arrows: Progress in Arrow RNAi Drugs

    All Arrows: Progress in Arrow RNAi Drugs

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Arrow today announced that its RNAi therapy ARO-HSD targeting HSD17B13 has shown certain early effects in a phase I clinical trial involving 5 NASH patients (the rest are healthy volunteers)


    Drug source analysis

    Drug source analysis

    With the success of the mRNA new crown vaccine, RNA drugs have entered the public eye


    RNAi is functionally the same as protein degradation technologies such as molecular glue and PROTAC


    Of course, RNA also has its own limitations, limited by delivery problems, the current targets are mainly focused on liver targets


    Genetic information ranges from DNA to RNA to protein.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.